{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:04:01Z","timestamp":1786550641000,"version":"3.56.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"W1","license":[{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["292611"],"award-info":[{"award-number":["292611"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["310507"],"award-info":[{"award-number":["310507"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["313267"],"award-info":[{"award-number":["313267"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["326238"],"award-info":[{"award-number":["326238"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006383","name":"Cancer Society of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9lius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union's Horizon 2020 Research and Innovation Programme"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>SynergyFinder (https:\/\/synergyfinder.fimm.fi) is a stand-alone web-application for interactive analysis and visualization of drug combination screening data. Since its first release in 2017, SynergyFinder has become a widely used web-tool both for the discovery of novel synergistic drug combinations in pre-clinical model systems (e.g. cell lines or primary patient-derived cells), and for better understanding of mechanisms of combination treatment efficacy or resistance. Here, we describe the latest version of SynergyFinder (release 2.0), which has extensively been upgraded through the addition of novel features supporting especially higher-order combination data analytics and exploratory visualization of multi-drug synergy patterns, along with automated outlier detection procedure, extended curve-fitting functionality and statistical analysis of replicate measurements. A number of additional improvements were also implemented based on the user requests, including new visualization and export options, updated user interface, as well as enhanced stability and performance of the web-tool. With these improvements, SynergyFinder 2.0 is expected to greatly extend its potential applications in various areas of multi-drug combinatorial screening and precision medicine.<\/jats:p>","DOI":"10.1093\/nar\/gkaa216","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T12:08:14Z","timestamp":1585138094000},"page":"W488-W493","source":"Crossref","is-referenced-by-count":834,"title":["SynergyFinder 2.0: visual analytics of multi-drug combination synergies"],"prefix":"10.1093","volume":"48","author":[{"given":"Aleksandr","family":"Ianevski","sequence":"first","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, FI-00290 Helsinki, Finland"},{"name":"Helsinki Institute for Information Technology (HIIT), Department of Computer Science, Aalto University, FI-02150 Espoo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K","family":"Giri","sequence":"first","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, FI-00290 Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-9769","authenticated-orcid":false,"given":"Tero","family":"Aittokallio","sequence":"first","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, FI-00290 Helsinki, Finland"},{"name":"Helsinki Institute for Information Technology (HIIT), Department of Computer Science, Aalto University, FI-02150 Espoo, Finland"},{"name":"Institute for Cancer Research, Department of Cancer Genetics, Oslo University Hospital, N-0310 Oslo, Norway"},{"name":"Oslo Centre for Biostatistics and Epidemiology (OCBE), Faculty of Medicine, University of Oslo, N-0317 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,4]]},"reference":[{"key":"2020062614043308000_B1","doi-asserted-by":"crossref","first-page":"e1002851","DOI":"10.1371\/journal.pmed.1002851","article-title":"Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: new technologies and innovative designs","volume":"16","author":"Davies","year":"2019","journal-title":"PLoS Med."},{"key":"2020062614043308000_B2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12936-018-2265-x","article-title":"Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis","volume":"17","author":"Adam","year":"2018","journal-title":"Malar. J."},{"key":"2020062614043308000_B3","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/14787210.2018.1544491","article-title":"Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults","volume":"16","author":"Properzi","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"2020062614043308000_B4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2016.11.017","article-title":"Synergistic drug combination effectively blocks Ebola virus infection","volume":"137","author":"Sun","year":"2017","journal-title":"Antiviral Res."},{"key":"2020062614043308000_B5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"2020062614043308000_B6","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.celrep.2014.02.007","article-title":"Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells","volume":"6","author":"Wood","year":"2014","journal-title":"Cell Rep."},{"key":"2020062614043308000_B7","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials","volume":"28","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"2020062614043308000_B8","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1158\/0008-5472.CAN-17-0489","article-title":"The National Cancer Institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity","volume":"77","author":"Holbeck","year":"2017","journal-title":"Cancer Res."},{"key":"2020062614043308000_B9","first-page":"93","article-title":"What is synergy","volume":"41","author":"Berenbaum","year":"1990","journal-title":"Pharmacol Rev."},{"key":"2020062614043308000_B10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann. App. Biol."},{"key":"2020062614043308000_B11","first-page":"286","article-title":"The problem of synergism and antagonism of combineddrugs","volume":"3","author":"Loewe","year":"1953","journal-title":"ArzneimiettelForschung"},{"key":"2020062614043308000_B12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"2020062614043308000_B13","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"key":"2020062614043308000_B14","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41375-018-0327-2","article-title":"Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)\/FLT3-ITD(+) acute myeloid leukemia","volume":"33","author":"Kivioja","year":"2019","journal-title":"Leukemia"},{"key":"2020062614043308000_B15","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1038\/s41467-018-07659-z","article-title":"Drug and disease signature integration identifies synergistic combinations in glioblastoma","volume":"9","author":"Stathias","year":"2018","journal-title":"Nat. Commun."},{"key":"2020062614043308000_B16","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1158\/0008-5472.CAN-17-3644","article-title":"Patient-Customized drug combination prediction and testing for T-cell prolymphocytic leukemia patients","volume":"78","author":"He","year":"2018","journal-title":"Cancer Res."},{"key":"2020062614043308000_B17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/1535-7163.MCT-19-0600","article-title":"Targeting histone chaperone FACT complex overcomes 5-Fluorouracil resistance in colon cancer","volume":"19","author":"Song","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"2020062614043308000_B18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ccell.2018.01.004","article-title":"Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations","volume":"33","author":"Jeselsohn","year":"2018","journal-title":"Cancer Cell"},{"key":"2020062614043308000_B19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/2159-8290.CD-18-0879","article-title":"MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF-, NRAS-, and NF1-Mutant melanomas","volume":"9","author":"Maertens","year":"2019","journal-title":"Cancer Discov."},{"key":"2020062614043308000_B20","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.drudis.2019.09.002","article-title":"Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls","volume":"24","author":"Vlot","year":"2019","journal-title":"Drug Discov. Today"},{"key":"2020062614043308000_B21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s42256-019-0122-4","article-title":"Prediction of drug combination effects with a minimal set of experiments","volume":"1","author":"Ianevski","year":"2019","journal-title":"Nat. Mach. Intell."},{"key":"2020062614043308000_B22","doi-asserted-by":"crossref","first-page":"e1007604","DOI":"10.1371\/journal.pcbi.1007604","article-title":"SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy","volume":"16","author":"Ianevski","year":"2020","journal-title":"PLoS Comput. Biol."},{"key":"2020062614043308000_B23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.15252\/msb.20156098","article-title":"Systematic discovery of drug interaction mechanisms","volume":"11","author":"Chevereau","year":"2015","journal-title":"Mol. Syst. Biol."},{"key":"2020062614043308000_B24","doi-asserted-by":"crossref","first-page":"10442","DOI":"10.1073\/pnas.1606301113","article-title":"Prediction of multidimensional drug dose responses based on measurements of drug pairs","volume":"13","author":"Zimmer","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2020062614043308000_B25","doi-asserted-by":"crossref","first-page":"e1701881","DOI":"10.1126\/sciadv.1701881","article-title":"Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis","volume":"3","author":"Cokol","year":"2017","journal-title":"Sci. Adv."},{"key":"2020062614043308000_B26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101612","article-title":"Identification of a synergistic Multi-Drug combination active in cancer cells via the prevention of spindle pole clustering","volume":"11","author":"Weiss","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2020062614043308000_B27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12859-019-2642-7","article-title":"Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets","volume":"20","author":"Amzallag","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"2020062614043308000_B28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cels.2019.10.004","article-title":"Emergent gene expression responses to drug combinations predict Higher-Order drug interactions","volume":"9","author":"Lukacisin","year":"2019","journal-title":"Cell Syst."},{"key":"2020062614043308000_B29","doi-asserted-by":"crossref","first-page":"e1006774","DOI":"10.1371\/journal.pcbi.1006774","article-title":"Prediction of ultra-high-order antibiotic combinations based on pairwise interactions","volume":"15","author":"Katzir","year":"2019","journal-title":"PLoS Comput. Biol."},{"key":"2020062614043308000_B30","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.18295\/squmj.2015.15.03.003","article-title":"A historical tale of two Lymphomas: part II: non-Hodgkin lymphoma","volume":"15","author":"Lakhtakia","year":"2015","journal-title":"Sultan Qaboos Univ. Med. J."},{"key":"2020062614043308000_B31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41540-018-0069-9","article-title":"Prevalence and patterns of higher-order drug interactions in Escherichia coli","volume":"4","author":"Tekin","year":"2018","journal-title":"NPJ Syst. Biol Appl."},{"key":"2020062614043308000_B32","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"2020062614043308000_B33","doi-asserted-by":"crossref","first-page":"14701","DOI":"10.1038\/srep14701","article-title":"An automated fitting procedure and software for dose-response curves with multiphasic features","volume":"5","author":"Di\u00a0Veroli","year":"2015","journal-title":"Sci. Rep."},{"key":"2020062614043308000_B34","doi-asserted-by":"crossref","first-page":"14421","DOI":"10.1038\/s41598-019-50936-0","article-title":"Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines","volume":"9","author":"Abbas-Aghababazadeh","year":"2019","journal-title":"Sci. Rep."},{"key":"2020062614043308000_B35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.vascn.2014.08.006","article-title":"Computational tools for fitting the Hill equation to dose\u2013response curves","volume":"71","author":"Gadagkar","year":"2015","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2020062614043308000_B36","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1039\/C8RA09652J","article-title":"Cisplatin, glutathione and the third wheel: a copper-(1,10-phenanthroline) complex modulates cisplatin\u2013GSH interactions from antagonism to synergism in cancer cells resistant to cisplatin","volume":"9","author":"Vascellari","year":"2019","journal-title":"RSC Adv."},{"key":"2020062614043308000_B37","doi-asserted-by":"crossref","DOI":"10.1101\/367664","article-title":"Transitions in interaction landscapes of multidrug combinations","author":"Kang","year":"2018"},{"key":"2020062614043308000_B38","doi-asserted-by":"crossref","first-page":"e1006677","DOI":"10.1371\/journal.pcbi.1006677","article-title":"Chemogenomic model identifies synergistic drug combinations robust to the pathogen microenvironment","volume":"14","author":"Cokol","year":"2018","journal-title":"PLoS Comput. Biol."}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/48\/W1\/W488\/33433098\/gkaa216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/48\/W1\/W488\/33433098\/gkaa216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T06:37:59Z","timestamp":1593239879000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/48\/W1\/W488\/5815821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,4]]},"references-count":38,"journal-issue":{"issue":"W1","published-online":{"date-parts":[[2020,4,4]]},"published-print":{"date-parts":[[2020,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkaa216","relation":{},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,2]]},"published":{"date-parts":[[2020,4,4]]}}}